{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:23:06Z","timestamp":1793164986547,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T00:00:00Z","timestamp":1195689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T00:00:00Z","timestamp":1195689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1038\/sj.leu.2405030","type":"journal-article","created":{"date-parts":[[2007,11,22]],"date-time":"2007-11-22T12:53:35Z","timestamp":1195736015000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes"],"prefix":"10.1038","volume":"22","author":[{"given":"G","family":"Buesche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Teoman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Wilczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Wilkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"G\u00f6hring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Georgii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kreipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,22]]},"reference":[{"key":"BF2405030_CR1","first-page":"307","volume":"154","author":"H Castro-Malaspina","year":"1984","unstructured":"Castro-Malaspina H, Jhanwar SC . Properties of myelofibrosis-derived fibroblasts. Prog Clin Biol Res 1984; 154: 307\u2013322.","journal-title":"Prog Clin Biol Res"},{"key":"BF2405030_CR2","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1365-2141.1994.tb04730.x","volume":"86","author":"A Kimura","year":"1994","unstructured":"Kimura A, Nakata Y, Hyodo H, Kuramoto A, Satow Y . Platelet-derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis. Br J Haematol 1994; 86: 303\u2013307.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2141.1993.tb04631.x","volume":"83","author":"JT Reilly","year":"1993","unstructured":"Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A . Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol 1993; 83: 58\u201362.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1365-2141.1989.tb04310.x","volume":"72","author":"A Kimura","year":"1989","unstructured":"Kimura A, Katoh O, Hyodo H, Kuramoto A . Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 1989; 72: 486\u2013491.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","volume":"11","author":"A Georgii","year":"1998","unstructured":"Georgii A, Buesche G, Kreft A . The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 1998; 11: 721\u2013749.","journal-title":"Baillieres Clin Haematol"},{"key":"BF2405030_CR6","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1038\/sj.leu.2403172","volume":"17","author":"G Buesche","year":"2003","unstructured":"Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia\u2014prospective long-term results from a randomized-controlled trial. Leukemia 2003; 17: 2444\u20132453.","journal-title":"Leukemia"},{"issue":"12","key":"BF2405030_CR7","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1038\/sj.leu.2404917","volume":"21","author":"G Buesche","year":"2007","unstructured":"Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007; e-pub ahead of print 6 September : doi:10.1038\/sj.leu.2404917.","journal-title":"Leukemia"},{"key":"BF2405030_CR8","first-page":"61","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"RD Brunning","year":"2001","unstructured":"Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001. pp 61\u201374."},{"key":"BF2405030_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","volume":"24","author":"U Germing","year":"2000","unstructured":"Germing U, Gattermann N, Strupp C, Aivado M, Aul C . Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983\u2013992.","journal-title":"Leuk Res"},{"key":"BF2405030_CR10","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood.V98.10.2935","volume":"98","author":"T Nosslinger","year":"2001","unstructured":"Nosslinger T, Reisner R, Koller E, Gruner H, Tuchler H, Nowotny H et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935\u20132941.","journal-title":"Blood"},{"key":"BF2405030_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189\u2013199.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01695890","volume":"66","author":"G Lambertenghi-Deliliers","year":"1993","unstructured":"Lambertenghi-Deliliers G, Annaloro C, Oriani A, Soligo D, Pozzoli E, Polli EE . Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 1993; 66: 85\u201391.","journal-title":"Ann Hematol"},{"key":"BF2405030_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1600-0609.1992.tb01587.x","volume":"48","author":"H Maschek","year":"1992","unstructured":"Maschek H, Georgii A, Kaloutsi V, Werner M, Bandecar K, Kressel MG et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 1992; 48: 208\u2013214.","journal-title":"Eur J Haematol"},{"key":"BF2405030_CR14","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/j.1365-2141.1995.tb05590.x","volume":"90","author":"I Cunningham","year":"1995","unstructured":"Cunningham I, MacCallum SJ, Nicholls MD, Byth K, Hewson JW, Arnold B et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 1995; 90: 602\u2013606.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR15","first-page":"141","volume":"75","author":"E Cassano","year":"1990","unstructured":"Cassano E, Giordano M, Riccardi A, Coci A, Cazzola M . Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system. Haematologica 1990; 75: 141\u2013145.","journal-title":"Haematologica"},{"key":"BF2405030_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/1097-0142(19910701)68:1<178::AID-CNCR2820680131>3.0.CO;2-Q","volume":"68","author":"K Ohyashiki","year":"1991","unstructured":"Ohyashiki K, Sasao I, Ohyashiki JH, Murakami T, Iwabuchi A, Tauchi T et al. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 1991; 68: 178\u2013183.","journal-title":"Cancer"},{"key":"BF2405030_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2141.1990.tb02612.x","volume":"75","author":"A Rios","year":"1990","unstructured":"Rios A, Canizo MC, Sanz MA, Vallespi T, Sanz G, Torrabadella M et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75: 26\u201333.","journal-title":"Br J Haematol"},{"key":"BF2405030_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF01698371","volume":"63","author":"GE Verhoef","year":"1991","unstructured":"Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 1991; 63: 235\u2013241.","journal-title":"Ann Hematol"},{"key":"BF2405030_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1385\/MO:21:4:325","volume":"21","author":"D Marisavljevic","year":"2004","unstructured":"Marisavljevic D, Rolovic Z, Cemerikic V, Boskovic D, Colovic M . Myelofibrosis in primary myelodysplastic syndromes: clinical and biological significance. Med Oncol 2004; 21: 325\u2013331.","journal-title":"Med Oncol"},{"key":"BF2405030_CR20","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. [published erratum appears in Blood 1998; 91: 1100] Blood 1997; 89: 2079\u20132088.","journal-title":"Blood"},{"key":"BF2405030_CR21","first-page":"35","volume-title":"World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"J Thiele","year":"2001","unstructured":"Thiele J, Vardiman JW, Pierre R, Brunning RD, Imbert M, Flandrin G . Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001. pp 35\u201338."},{"key":"BF2405030_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.2003.04.182","volume":"21","author":"E Verburgh","year":"2003","unstructured":"Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21: 273\u2013282.","journal-title":"J Clin Oncol"},{"key":"BF2405030_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1053\/hupa.2003.58","volume":"34","author":"G Buesche","year":"2003","unstructured":"Buesche G, Georgii A, Duensing A, Schlue J, Kreipe HH . Evaluating the volume ratio of bone marrow affected by fibrosis\u2014a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol 2003; 34: 391\u2013401.","journal-title":"Hum Pathol"},{"key":"BF2405030_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/gcc.1112","volume":"31","author":"S Metzke-Heidemann","year":"2001","unstructured":"Metzke-Heidemann S, Harder L, Gesk S, Schoch R, Jenisch S, Grote W et al. Integration of amplified BCR\/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia. Genes Chromosomes Cancer 2001; 31: 10\u201314.","journal-title":"Genes Chromosomes Cancer"},{"key":"BF2405030_CR25","volume-title":"An International System for Human Cytogenetic Nomenclature","author":"F Mitelman","year":"1995","unstructured":"Mitelman F, (ed)., ISCN (1995). An International System for Human Cytogenetic Nomenclature. Karger: Basel, Switzerland, 1995."},{"key":"BF2405030_CR26","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2353\/ajpath.2006.060110","volume":"169","author":"O Bock","year":"2006","unstructured":"Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 2006; 169: 471\u2013481.","journal-title":"Am J Pathol"},{"key":"BF2405030_CR27","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2006-05-022491","volume":"109","author":"N Gattermann","year":"2007","unstructured":"Gattermann N, Billiet J, Kronenwett R, Zipperer E, Germing U, Nollet F et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count&gt;600 \u00d7 109\/l) and ringed sideroblasts more than 15% considered as MDS\/MPD, unclassifiable. Blood 2007; 109: 1334\u20131335.","journal-title":"Blood"},{"key":"BF2405030_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/sj.leu.2404215","volume":"20","author":"W Ingram","year":"2006","unstructured":"Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006; 20: 1319\u20131321.","journal-title":"Leukemia"},{"key":"BF2405030_CR29","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","volume":"106","author":"DP Steensma","year":"2005","unstructured":"Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u2018atypical\u2019 myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106: 1207\u20131209.","journal-title":"Blood"},{"key":"BF2405030_CR30","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/sj.leu.2403989","volume":"19","author":"K Ohyashiki","year":"2005","unstructured":"Ohyashiki K, Aota Y, Akahane D, Gotoh A, Miyazawa K, Kimura Y et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia 2005; 19: 2359\u20132360.","journal-title":"Leukemia"},{"key":"BF2405030_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.leukres.2003.10.016","volume":"28","author":"J Cermak","year":"2004","unstructured":"Cermak J, Vitek A, Michalova K . Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation. Leuk Res 2004; 28: 551\u2013557.","journal-title":"Leuk Res"},{"key":"BF2405030_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/asheducation-2005.1.161","volume":"2005","author":"E Hellstrom-Lindberg","year":"2005","unstructured":"Hellstrom-Lindberg E . Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology (Am Soc Hematol Educ Program) 2005; 2005: 161\u2013166.","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"BF2405030_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56\u201363.","journal-title":"Microvasc Res"},{"key":"BF2405030_CR34","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1056\/NEJMoa041668","volume":"352","author":"A List","year":"2005","unstructured":"List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549\u2013557.","journal-title":"N Engl J Med"},{"key":"BF2405030_CR35","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/sj.leu.2403239","volume":"18","author":"M Stadler","year":"2004","unstructured":"Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460\u2013465.","journal-title":"Leukemia"},{"key":"BF2405030_CR36","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0145-2126(01)00061-3","volume":"25","author":"S Alvi","year":"2001","unstructured":"Alvi S, Shaher A, Shetty V, Henderson B, Dangerfield B, Zorat F et al. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leuk Res 2001; 25: 941\u2013954.","journal-title":"Leuk Res"},{"key":"BF2405030_CR37","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0145-2126(01)00193-X","volume":"26","author":"E Flores-Figueroa","year":"2002","unstructured":"Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H . In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 2002; 26: 677\u2013686.","journal-title":"Leuk Res"},{"key":"BF2405030_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.leukres.2003.11.019","volume":"28","author":"R Borojevic","year":"2004","unstructured":"Borojevic R, Roela RA, Rodarte RS, Thiago LS, Pasini FS, Conti FM et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leuk Res 2004; 28: 831\u2013844.","journal-title":"Leuk Res"},{"key":"BF2405030_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2559.2005.02302.x","volume":"48","author":"G Buesche","year":"2006","unstructured":"Buesche G, Georgii A, Kreipe HH . Diagnosis and quantification of bone marrow fibrosis are significantly biased by the pre-staining processing of bone marrow biopsies. Histopathology 2006; 48: 133\u2013148.","journal-title":"Histopathology"},{"key":"BF2405030_CR40","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1038\/sj.leu.2403963","volume":"19","author":"U Germing","year":"2005","unstructured":"Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223\u20132231.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2405030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2405030","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2405030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T03:00:22Z","timestamp":1648782022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2405030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,22]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["BF2405030"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2405030","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,22]]},"assertion":[{"value":"31 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2007","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2007","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}